Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate (ADC), trumpeting a 100% complete response rate but also reporting safety signals that informed the decision to take the low ...
Daiichi Sankyo and Merck & Co.’s phase 3 program for their investigational antibody-drug conjugate has been hit with a hold after an unexpected number of deaths were reported in the global trial. “Due ...
Oct. 14, days before the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Merck & Co. published a new clinical trial of sacituzumab tirumotecan (sac-TMT), in combination with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results